To test this, we assessed drug sensitivity across six genetically diverse AML cell lines harboring MLL rearrangements (MOLM-13, MV4–11), the AML1-ETO translocation (SKNO-1, KASUMI-1), NPM1/DNMT3A mutations (OCI-AML3), and a TP53 mutation (U-937). This evidence concerns the gene RUNX2 and acute myeloid leukemia.